Table 2.
Drug class mutations observed by NGS at different mutation thresholds.
| Mutations detected | Detection threshold | ||||
|---|---|---|---|---|---|
| 1%–2% | >2%–5% | >5%–10% | >10%–<20% | ≥20% | |
| NRTI-associated | |||||
| M41L | 0 | 0 | 0 | 0 | 1 |
| A62V | 0 | 0 | 0 | 0 | 1 |
| K65R | 6 | 2 | 0 | 0 | 0 |
| V75I | 0 | 1 | 1 | 0 | 0 |
| F77L | 0 | 1 | 0 | 0 | 0 |
| F116Y | 0 | 1 | 0 | 0 | 0 |
| M184I | 0 | 1 | 0 | 0 | 0 |
| M184V | 0 | 1 | 0 | 0 | 0 |
| Total | 6 | 7 | 1 | 0 | 2 |
| NNRTI-associated | |||||
| K103N | 0 | 0 | 1 | 0 | 2 |
| V106M | 1 | 0 | 0 | 0 | 0 |
| V108I | 1 | 1 | 0 | 1 | 0 |
| E138G | 1 | 1 | 0 | 0 | 0 |
| E138K | 1 | 1 | 0 | 0 | 0 |
| Y181C | 1 | 0 | 0 | 0 | 0 |
| Y188C | 0 | 1 | 0 | 0 | 0 |
| Y188H | 1 | 0 | 0 | 0 | 0 |
| P225H | 1 | 0 | 0 | 0 | 0 |
| M230I | 1 | 0 | 0 | 0 | 0 |
| Total | 8 | 4 | 1 | 1 | 2 |
| PI-associated | |||||
| M46I | 2 | 2 | 0 | 1 | 0 |
| M46L | 0 | 1 | 0 | 0 | 0 |
| I50V | 1 | 0 | 0 | 0 | 0 |
| T74P | 1 | 0 | 0 | 0 | 0 |
| I84V | 1 | 1 | 0 | 0 | 0 |
| N88S | 0 | 1 | 0 | 0 | 0 |
| Q58E | 0 | 0 | 0 | 0 | 2 |
| Total | 5 | 5 | 1 | 1 | 2 |
NGS = next-generation sequencing; NRTI = nucleoside reverse-transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = Protease inhibitor. Mutations detected at >20% were also detected by Sanger sequencing.